Renaissance Capital logo

Pain treatment biotech Recro Pharma files for a $28 million IPO

October 24, 2013

Recro Pharma, a clinical-stage biotech developing non-opioid therapeutics for the treatment of pain, filed on Thursday with the SEC to raise up to $28 million in an initial public offering. The Malvern, PA-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol REPH. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.